Trilostate: Uses, Benefits, and Side Effects Explained

Trilostane is a synthetic, orally active medication used primarily in the treatment of Cushing’s disease (hyperadrenocorticism) in dogs and, to a lesser extent, in humans. It acts as a competitive inhibitor of the enzyme 3β-hydroxysteroid dehydrogenase, which is involved in the synthesis of cortisol and other steroids.

Medical Uses

Cushing’s Disease (Hyperadrenocorticism)

The primary use of Trilostane is in the management of Cushing’s disease, a condition characterized by excessive production of cortisol by the adrenal glands. In both humans and animals, Cushing’s disease can lead to various symptoms, including hyperadrenocorticism symptoms such as increased thirst, increased urination, muscle wasting, and a potbellied appearance.

Trilostane is often the treatment of choice for Cushing’s syndrome management in dogs, as it has proven to be effective and generally well-tolerated. It works by inhibiting the synthesis of cortisol, thereby reducing the excess levels of this hormone.

Alopecia X

In addition to its use in Cushing’s disease, Trilostane has also been explored as a potential treatment for Alopecia X, a condition characterized by hair loss in dogs. While the exact mechanisms are not fully understood, it is believed that Trilostane may help in Alopecia X by modulating hormone levels and reducing the production of certain steroids.

Conn’s Syndrome and Other Conditions

Trilostane has also been investigated for its potential use in the treatment of Conn’s syndrome, a condition characterized by excessive production of aldosterone by the adrenal glands. By inhibiting the synthesis of aldosterone, Trilostane may help manage the symptoms associated with this condition.

Researchers are exploring the potential applications of Trilostane in other cortisol-related conditions, such as certain forms of hypertension and certain types of cancers.

Veterinary Use

The primary use of Trilostane is in the treatment of hyperadrenocorticism (Cushing’s disease) in dogs. It is a widely accepted and effective treatment option for this condition in veterinary medicine.

Trilostane is typically administered orally, either in capsule form or as a compounded formulation, to dogs diagnosed with Cushing’s disease. The medication works by inhibiting the production of cortisol, thereby reducing the excessive levels of this hormone that contribute to the symptoms of the disease.

Veterinarians closely monitor dogs receiving Trilostane therapy, as dosage adjustments may be necessary based on clinical signs and cortisol levels. Regular checkups and laboratory tests are typically performed to ensure the medication is working effectively and to monitor for potential side effects.

Trilostane has also been explored for use in other species, such as cats and horses, but its primary use remains in the treatment of canine Cushing’s disease.

Administration and Dosage

Trilostane is typically administered orally, either in capsule form or as a compounded formulation. The recommended dosage for the treatment of Cushing’s disease in dogs is typically around 2-6 mg/kg body weight, given once every 12 hours (q12h).

The exact dosage may vary depending on the individual dog’s response to the medication, as well as the severity of the condition. Veterinarians will closely monitor the dog’s clinical signs, as well as cortisol levels, and adjust the dosage accordingly.

It is important to follow the manufacturer’s recommendations and your veterinarian’s instructions regarding the administration and dosage of Trilostane. Failure to do so can result in inadequate treatment or potential side effects.

Mechanism of Action

Trilostane is a synthetic, orally active medication that acts as a competitive inhibitor of the enzyme 3β-hydroxysteroid dehydrogenase (3β-HSD). This enzyme plays a crucial role in the synthesis of cortisol and other steroid hormones.

By inhibiting 3β-HSD, Trilostane effectively inhibits the synthesis of cortisol and other steroids derived from pregnenolone. This reduction in cortisol levels is the primary mechanism by which Trilostane helps manage Cushing’s disease and other conditions associated with excessive cortisol production.

While Trilostane inhibits the synthesis of cortisol and other steroids, it does not completely block their production. This allows for the maintenance of essential steroid levels necessary for normal physiological functions.

Clinical Trials and Studies

Numerous clinical trials and studies have been conducted to evaluate the efficacy, safety, and dosing of Trilostane in both human and veterinary medicine.

In veterinary medicine, several studies have demonstrated the effectiveness of Trilostane in the treatment of hyperadrenocorticism (Cushing’s disease) in dogs. These studies have shown that Trilostane can effectively reduce cortisol levels and alleviate associated clinical signs, with a relatively low incidence of adverse effects.

In humans, clinical trials have explored the use of Trilostane in the management of Cushing’s disease, as well as other conditions such as Conn’s syndrome and certain types of cancers. While the results have been promising, further research is still needed to fully understand the potential benefits and risks of Trilostane in human medicine.

Side Effects and Contraindications

While generally well-tolerated, Trilostane can cause side effects in some patients or pets. The most common side effects observed in dogs receiving Trilostane include:

• Lethargy
• Inappetence
• Vomiting
• Diarrhea
• Weakness

These side effects are typically mild and may resolve on their own or with dose adjustments. However, in some cases, more severe side effects can occur, such as adrenal insufficiency or electrolyte imbalances.

Trilostane is contraindicated in animals with known hypersensitivity to the medication or in cases of adrenal insufficiency. It should be used with caution in animals with liver or kidney disease, as well as in pregnant or lactating animals.

It is important to closely monitor animals receiving Trilostane therapy and to report any concerning signs or symptoms to your veterinarian promptly.

Commercial Availability

Trilostane is available commercially under the brand name Vetoryl, which is marketed specifically for the treatment of Cushing’s disease (hyperadrenocorticism) in dogs.

Vetoryl is available in capsule form, with strengths of 5 mg, 10 mg, 30 mg, and 120 mg. The capsules are designed to be administered orally, either whole or opened and mixed with a small amount of food.

In addition to the branded Vetoryl capsules, compounded formulations of Trilostane may also be available through specialized veterinary pharmacies.

Regulatory Status

Trilostane has been approved for veterinary use in several countries, including the United States, Canada, and several European countries.

In the United States, Vetoryl ( Trilostane) capsules were approved by the Food and Drug Administration (FDA) in 2008 for the treatment of hyperadrenocorticism (Cushing’s disease) in dogs. It is available through veterinary prescription only.

In Europe, Trilostane has been approved for use in several countries, including the United Kingdom, France, and Germany, under various brand names.

It is important to note that regulatory status and availability may vary in different countries, and veterinarians should consult local regulations and guidelines for the appropriate use of Trilostane in their respective regions.

Interactions with Other Medications

While Trilostane is generally well-tolerated when used as directed, there is a potential for interactions with other medications. It is important to inform your veterinarian of all medications and supplements your pet is taking to avoid potential drug interactions.

Some of the potential drug interactions with Trilostane include:

• Medications that induce or inhibit liver enzymes (e.g., certain antibiotics, antifungals, and anti-seizure medications)
• Corticosteroids and other hormonal therapies
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Certain chemotherapeutic agents

Your veterinarian may need to adjust the dosage or monitor your pet more closely if they are taking medications that interact with Trilostane.

Patient and Pet Owner Information

If your pet is prescribed Trilostane, it is important to follow your veterinarian’s instructions carefully. This includes administering the medication as directed, monitoring for potential side effects, and keeping scheduled follow-up appointments for monitoring and dosage adjustments.

Pet owners should be aware of the signs and symptoms of Cushing’s disease, as well as the potential side effects of Trilostane therapy. It is important to report any unusual behavior, appetite changes, or other concerning signs to your veterinarian promptly.

Trilostane should be stored as directed, typically at room temperature and away from moisture and direct sunlight. It is also important to keep the medication out of reach of children and other pets.

Future Directions and Ongoing Research

Ongoing research continues to explore the potential applications of Trilostane in both human and veterinary medicine. Some areas of focus include:

• Development of new formulations or delivery systems for improved bioavailability and patient compliance
• Evaluation of Trilostane‘s efficacy in the treatment of other endocrine disorders or hormone-related conditions
• Further understanding of the long-term effects and safety profiles of Trilostane therapy
• Exploration of combination therapies involving Trilostane and other medications or treatment modalities

As research continues, the applications and understanding of Trilostane‘s therapeutic potential may expand, potentially benefiting both human and animal patients.

Historical Development

Trilostane was first developed in the 1970s as a potential treatment for Cushing’s syndrome and other conditions involving excessive cortisol production.

Early studies demonstrated its effectiveness as a competitive inhibitor of the enzyme 3β-hydroxysteroid dehydrogenase, which plays a crucial role in the synthesis of cortisol and other steroids.

Throughout the 1980s and 1990s, further research explored the potential applications of Trilostane in both human and veterinary medicine. In the late 1990s and early 2000s, Trilostane began to gain widespread acceptance as a treatment option for Cushing’s disease in dogs.

In 2008, the FDA approved Vetoryl ( Trilostane) capsules for the treatment of hyperadrenocorticism in dogs, solidifying its position as a standard treatment option in veterinary endocrinology.

Alternative Treatments

While Trilostane is considered one of the primary treatment options for Cushing’s disease in dogs, there are alternative treatments available depending on the underlying cause and severity of the condition.

Some alternative treatments for Cushing’s disease in dogs include:

• Surgery: In cases where the excessive cortisol production is caused by an adrenal tumor, surgical removal of the affected adrenal gland(s) may be recommended.
• Radiation therapy: Radiation therapy may be used to shrink or control the growth of adrenal tumors in some cases.
• Other medications: Medications such as selegiline (Anipryl) or mitotane (Lysodren) may be used as alternative or complementary treatments to Trilostane.

The choice of treatment will depend on various factors, including the underlying cause of the disease, the severity of the condition, the age and overall health of the dog, and the potential side effects and risks